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Summary 
Background: In allergic responses a distinction is made between an early phase 
response, several minutes after allergen exposure, and a late phase response 
after several hours. During the late phase, eosinophils and T cells infiltrate in 
the mucosa and play an important role in inflammation. 
Objective: To examine the relationship between allergen-induced late phase 
skin responses and in vitro T cell reactivity. In addition, the relationship between 
allergen-induced skin or T cell responses and the severity of self-reported 
symptoms was studied in children with house dust mite allergy. 
Methods: A total of 59 house-dust-mite allergic children (6-18 years) were 
recruited in general practice. These children or their parents rated their nasal 
and asthma symptoms on diary cards during one month. Allergen skin tests 
were performed and read after 15 minutes (early phase) and 6 hours (late 
phase). Allergen-specific T cell proliferation was determined and Th2 cytokine 
(IL-5 and IL-13) secretion was analyzed. 
Results:  The size of the late phase skin response correlated with in vitro T cell 
proliferation (rs=0.38, p=0.003) but not with Th2 cytokine secretion (rs=0.16, 
p=0.2 both for IL-5 and IL-13).  Moreover, the late phase skin response and T 
cell proliferation correlated with asthma symptoms (rs=0.30, p=0.02 for skin 
response and rs=0.28, p=0.03 for T cell proliferation) but not with nasal 
symptoms (rs=0.19, p=0.15 for skin response and rs=0.09, p=0.52 for T cell 
proliferation). The early phase skin response correlated with the nasal symptom 
score (rs=0.34, p=0.01) but not with asthma symptom scores (rs<0.005,p=0.97). 
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Conclusion: In this study the late phase skin test response correlated with in 
vitro T cell proliferation but not with Th2 cytokine secretion. We found weak or 
absent correlations between late phase skin responses and symptoms of 
asthma or rhinitis in children with house dust mite allergy. This suggests that 
late phase skin responses reflect certain T cell properties but are of limited 
value for the evaluation of airway symptoms in atopic children. 
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Introduction 
 
Allergic rhinitis (AR) is an inflammatory condition in which symptoms are not 
confined to an early phase response within minutes after allergen exposure, but 
may be present several hours after allergen contact (late phase response). 
Symptoms of the early phase response are sneezing, itching and rhinorrhea. 
During the late phase response congestion, fatigue, malaise, and irritability 
become more prominent. During this late phase, inflammatory cells such as 
eosinophils and T cells infiltrate the mucosa. Especially Th2 cytokines, such as 
IL-4, IL-5 and IL-13, play a central role in the late phase allergic response. 1-3 
As in AR, early and late inflammatory changes in the bronchi of asthmatic 
patients, with influx of activated eosinophils and T cells, can be demonstrated.4-6 
Both nasal and bronchial mucosa are elements of a "united airway" and 
therefore AR and asthma are both manifestations of the same allergic disease.4 
As a consequence, asthma and rhinitis often coexist in the same patients. It 
appears that at least 80% of asthmatic patients suffer from rhinitis and around 
20-30% of patients with AR also have asthma.2,7   
In vivo skin testing or detection of in vitro allergen-specific responses can be 
helpful to test whether a patient with a relevant clinical history is allergic to a 
specific allergen. After intradermal injection of allergen in the skin of a sensitive 
subject a type-I reaction develops rapidly, peaks after 10-20 min, and subsides 
within a few hours. After several hours a late diffuse edematous response may 
appear at the allergen injection site.8 In vitro, allergen-specific T cell responses 
and Th2 cytokine production can be assessed. 
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In this study we hypothesized that the extent of the late phase skin response in 
house dust mite (HDM)-allergic children is associated with in vitro T cell activity 
to HDM, since these are both manifestations of the late phase inflammatory 
response. To test this hypothesis, we investigated skin responses after 
intradermal injection of HDM and determined allergen-induced T cell 
proliferation and Th2 cytokine production. In addition, we examined the 
relationship between in vivo skin testing or in vitro T cell response and the 
severity of self-reported nasal or bronchial symptoms in children with a proven 
HDM allergy.  
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Methods and subjects 
 
Patient selection 
Fifty-nine children (aged 6 to 18 years) with allergic rhinitis and established 
HDM allergy were selected from electronic medical records in general practice. 
The inclusion criteria were: presence of  specific IgE antibodies to HDM in 
serum (≥ 0.7 kU/l), a history of allergic rhinitis during at least 1 year, and a nasal 
symptom score of at least 4 out of 12 (see below). Before scoring symptoms, 
nasal corticosteroids were withheld for 4 weeks before the study period. The 
presence of asthma was assessed using the International Study of Asthma and 
Allergies in Childhood (ISAAC) core questionnaire.9 
The study was approved by the ethical review board of Erasmus MC. All 
patients and / or their parents gave informed consent for the study. 
 
Measurement of nasal or asthma symptoms 
All participants or their parents scored their nasal symptoms on diary cards 
during a period of 1 month in October or in November. Nasal symptoms 
(sneezing, itching nose, watery running nose and nasal blockage) were scored 
on a 0-3 scale (0=none, 1=mild, 2=moderate, 3=severe). In total, a maximal 
daily cumulative nasal symptom score of 12 could thus be obtained. Children or 
parents scored their asthma symptoms (wheeze/breathless and dry cough 
during night) daily during 1 month on diary cards. In total, a maximum daily 
asthma symptom score of 6 (0-3 for wheeze/breathless and 0-3 for dry cough 
during night) could be obtained.  
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A mean symptom score was determined by calculating the mean daily score 
over the entire month. Only diaries with at least 15 out of 30 completely filled 
out pages were included in the analyses. 
 
Skin testing 
Allergy skin testing was performed by intracutaneous injection of 0.02 ml 
Dermatophagoides pteronyssinus in the forearm (concentration 30 U/ml, 
manufactured by ALK-Abelló, Nieuwegein, the Netherlands). We chose to 
perform an intracutaneous skin test rather than the usual skin prick test 
because intracutaneous injection of the allergen is the most feasible and 
convenient way to induce a late phase response after the early phase skin 
response.8 As a positive control, histamine (concentration 0.01 mg/ml) was 
injected, negative control was dilution buffer. Reactions were read after 15 min 
(early response) and after 6 h (late response). The area of the skin response in 
mm2 was measured by a specially developed scanning program. The early 
phase response was considered positive when its size was at least half the size 
of the histamine response (expressed as a Histamine-Equivalent-Intra-
Cutaneous index or HEIC index). This cut-off value was determined by applying 
a modified algorithm proposed by Niemijer et al.10 Late phase skin responses 
with a surface of more than 100 mm2 were regarded positive, a surface of 50-
100 mm2 was considered borderline. Children were not allowed to take 
antihistamines within 24 h prior to skin testing. 
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HDM-specific T cell proliferation 
Blood was drawn before skin testing. Peripheral blood mononuclear cells 
(PBMC) were isolated from heparinized blood by density centrifugation on 
Ficoll-Paque Plus (GE Healthcare, Uppsala, Sweden). PBMCs were used in a 
lymphocyte proliferation test (LPT). Cells were resuspended in complete 
medium (RPMI+HEPES+glutamax supplemented with gentamicin (Gibco, Gibco 
BRL, Life Technologies, Rockville, USA) and 5% heat inactivated human serum 
(Sanquin, Rotterdam, the Netherlands) and stimulated by culturing in the 
presence or absence of 2 IR/ml D. pteronyssinus (Stallergènes, France).  All 
cell cultures were performed in quadruplicate in a final volume of 200 ml with a 
cell concentration of 2x106 cells/ml in 96-well round bottomed microtitre plates. 
To determine HDM-specific proliferative responses, cells were cultured for 5 
days at 37°C, 5% CO2, 95% humidity. During the last 16 h, cells were pulsed 
with 0.5 μCi/well 3H thymidine (Pharmacia, UK). Radioactivity was measured 
with a β-platereader and the proliferative capacity was assessed by the 
stimulation index (SI), calculated as the ratio of mean 3H thymidine uptake in 
stimulated to non-stimulated cultures. The SI was considered positive when it 
exceeded 2.0. 
 
HDM-specific cytokine production 
To determine HDM-specific cytokine production, 1 ml of PBMCs with a 
concentration of 2x106 cells/ml were cultured in duplicate in a 24-well plate with 
or without 2 IR/ml D. pteronyssinus (Stallergènes, France). After 5 days of 
culture, supernatants were harvested and stored at –20 °C until testing. IL-5, IL-
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13, and IFN-γ cytokine production was measured following the manufacturer’s 
instructions (for IL-5 and IFN-γ eBioscience, San Diego, USA; for IL-13 R&D 
Systems, Abingdon, UK). The lower detection limits for these cytokines are: 7.8 
pg/ml for IL-5; 3.1 pg/ml for IL-13 and 12.5 pg/ml for IFN-γ. HDM-induced 
cytokine production was assessed by subtracting the cytokine concentration of 
non-stimulated from stimulated culture supernatants. 
 
Measurement of exhaled NO 
Exhaled nitric oxide (NO) was measured with a handheld FENO device (NIOX 
MINO, Aerocrine Solna, Sweden) in accordance with the manufacturers 
guidelines and literature references11. Exhalation duration was 10 seconds for 
all children.  
 
Statistical analysis 
Associations between variables were assessed using Spearman’s correlation 
coefficient (rs), since data were not normally distributed. A p-value of 0.05 (2-
sided) was considered to be the limit of significance in all analyses. SPSS 11.0 
for Windows was used for all analyses. 
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Results 
 
Clinical characteristics of the study population 
Baseline characteristics of the 59 children are summarized in Table 1. All 
children had elevated serum concentrations of HDM-specific IgE antibodies 
(mean 43.2 kU/l, range 0.7 to >100 kU/l). The mean daily nasal symptom score 
was 3.4 (range 0.3 to 8.8). Of the 59 children, 27 (46%) reported an earlier 
physician’s diagnosis of asthma. However, 70% of children reported wheeze. 
The mean asthma symptom score was 0.9 (range 0 to 5.4) for the total group. 
Patients diagnosed as having asthma had an asthma symptom score of 1.4 
whereas children without asthma had a score of 0.4 (p=0.002). 
The early phase skin response to HDM was determined in 52 patients only. A 
positive response was detected in 51/52 patients (98%). Of the 59 children, 48 
(81%) had a positive late phase skin response and 7/59 (12%) had a borderline 
positive late response.  
 
Correlation between in vivo skin tests and in vitro T cell responses 
Positive HDM-specific T cell proliferation responses were found in 51/59 (86%)  
and Th2 cytokine production was found in 44/59 (75%) of children. The size of 
the early phase skin response showed a borderline significant correlation with T 
cell proliferation (rs=0.25, p=0.07) and a significant positive correlation with 
cytokine secretion (rs=0.3, p= 0.03 for both cytokines). The size of the late 
phase skin response correlated significantly with in vitro T cell proliferation 
(rs=0.38, p=0.003, fig 1a) but not with cytokine secretion (rs=0.16, p=0.2 both for 
IL-13 and IL-5, fig 1b).  
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The size of early phase and late phase skin responses demonstrated a clear 
positive correlation within subjects (rs=0.51, p<0.001). In vitro T cell proliferation 
and cytokine production also showed a positive association (rs=0.34, p=0.01 for 
IL-5 and rs=0.36, p=0.01 for IL-13). 
 
Correlation between skin responses and nasal or asthma symptoms 
The early phase skin response correlated with the nasal symptom score 
(rs=0.34, p=0.01; fig 2a) but not with asthma symptom scores (rs<0.005, p=0.97, 
fig 2b), whereas the late response correlated with asthma symptoms (rs=0.30, 
p=0.02, fig 2d) but not with nasal symptoms (rs=0.19, p=0.15, fig 2c). 
 
Correlation between T cell responses and nasal or asthma symptoms 
Allergen-specific T cell proliferation was associated with asthma symptoms 
(rs=0.28, p=0.03) but not with nasal symptoms (rs=0.09, p=0.52). Cytokine 
production (both IL-5 and IL-13) did not correlate with nasal symptoms (rs=0.14 
for IL-5 and rs=0.02 for IL-13) or bronchial symptoms (rs=0.14 for IL-5 and 
rs=0.15 for IL-13). Next to allergen-specific T cell responses and asthma 
symptoms, exhaled NO was determined as a measure for asthma disease 
severity. There was no correlation between the level of exhaled NO and disease 
severity (i.e. asthma symptom score, Rs=0.134, p=0.32). However, exhaled NO 
correlated with in vitro T cell proliferation (Rs=0.363, p=0.005)  and Th2 cytokine 
production (Rs=0.427, p=0.001 for IL-5 and Rs=0.350, p=0.007 for IL-13). 
H. Moed et al 12 
Discussion 
The results of the present study show that in HDM-allergic children in vivo late 
phase skin responses correlate with in vitro T cell proliferation but not with Th2 
cytokine secretion. Correlations between skin tests and T cell responses on the 
one hand and atopic airway symptoms on the other were weak and 
inconsistent.  
 
Allergen-specific T cells play an important role in the development of a late 
phase allergen response. A subset of Th2 lymphocytes upon activation produce 
cytokines such as IL-13, IL-5 and IL-4.12 Especially IL-5 is responsible for the 
cascade of eosinophil activation, whereas IL-13 and IL-4 are crucial in IgE 
production.13 Whereas an association emerged between the extent of a late 
phase skin response and the level of the in vitro T cell proliferation, no 
correlation was found between the extent of the late phase skin reaction and 
production of Th2 cytokines. So, whereas there is an involvement of allergen-
specific T cells in the late phase response, we were not able to attribute this to 
Th2 cells in particular. 
Other studies report a lack of correlation between absolute amounts of IL-5 or 
IL-13 secretion and proliferative responses.14,15 Perhaps a combination of 
qualitative (i.e. cytokine profiles) and quantitative responses (i.e. proliferation 
rate) serve to characterize the allergic responder phenotype. 
It is possible that cytokines were derived from basophils rather than T cells. 
Recent evidence suggests that basophils are an important source of cytokines 
such as interleukin-4, perhaps more important than T cells. This would make 
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any correlation involving cytokine production and T cell activity difficult to 
interpret. 
A correlation between late asthmatic response (LAR) and inflammation (i.e. 
allergen-specific proliferative response of T cells) has been reported.16 
However, no contribution of the late cutaneous response was found in 
association with LAR or inflammation; the lack of a relationship between 
allergen-induced late inflammatory response in the skin and airways in the latter 
study could be explained by variations in measurement. 
Very few studies have addressed the association between clinical symptoms 
and the outcome of in vivo and in vitro tests. In two studies the severity of 
asthma appeared to be associated with the number of positive skin tests and 
the magnitude of the immediate skin reaction17 or with total and specific IgE.18 
In seasonal allergic rhinitis skin tests do not predict symptom severity in the 
pollen season.19  
More research has focused on the relationship between in vivo or in vitro tests 
and allergen-specific bronchial16,20-22 or nasal22 airway reactivity.  
In line with previous challenge studies16,21 our results suggest that asthmatic 
complaints are related to late inflammatory changes, i.e. the level of allergen-
specific proliferative response of T cells in vitro and the late phase cutaneous 
response in vivo. In our study, the early skin response is not correlated with 
asthmatic complaints, but with nasal symptoms, whereas the late phase 
cutaneous reaction was not related with rhinitis severity. Also, the nasal allergic 
reaction is better predicted by immediate skin test than by late skin reactions.23 
However, all challenge studies demonstrate that non-specific airway reactivity is 
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more important in predicting airway reactivity to allergens than indices of allergic 
sensitization. This might, in part, explain the weak correlations found in the 
present study. 
 
Whereas in both AR and asthma early and late phase responses play an 
important role,24 it seems feasible that sneezing and itching are features of an 
early phase response, and that during the late phase response asthma and 
nasal congestion are more prominent. During the early phase response, 
histamine and leukotrienes are important mediators that are generated from 
resident airway cells. Therefore, antihistamines and anti-leukotrienes are 
effective against direct complaints of the nose and the early skin response.5  
 
Limitations of the study 
Correlations in our study were significant but not strong. This might be 
explained by the fact that the complaints of patients are determined by many 
factors, such as degree of sensitization, allergen exposure, non-specific airway 
hyperresponsiveness, experience, use of specific medication, and symptom 
perception. Since the interaction between all these variables influences the 
outcome, we would not expect a high correlation coefficient.  
Another explanation might be that children were allowed to take symptomatic 
asthma or allergy medication in case of complaints. This might result in a 
decrease of self-reported symptoms, and a weaker correlation between T cell 
responses and symptoms.  
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In conclusion, we have shown a correlation between late phase allergen-
induced skin responses and T cell proliferation, but not Th2 cytokine secretion. 
Elevated levels of Th2 cytokines did not correlate with the late phase response 
or with clinical symptoms. We speculate that both late phase skin tests and in 
vitro T cell tests reflect immunological abnormalities in atopic children, but that 
other mechanisms determine the severity of reported atopic symptoms.  
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Table 1: Characteristics of the study population
n = 59
Age - years (Mean, SD) 11.6 (2.9)
Gender - Male (n, %) 28 (48%)
Weight - kg (Mean, SD) 47 (14)
Height - cm (Mean, SD) 153 (16)
FeNO - ppb (Mean - Range) 38 (4-173)
Allergy / Asthma symptoms
Nasal symptom score (Mean, Range) 3.4 (0.3 - 8.8)
Asthma symptom score (Mean, Range) 0.9 (0.0 - 5.4)
In vivo HDM specific skin test
Early skin test - HEIC (Mean, Range) 1.7 (0.4 - 3.3)
Late skin test - mm
2
 (Mean, Range) 871 (0 - 2728)
In vitro HDM specific allergy test
specific IgE - kU/L (Mean, Range) 43.2 (0.7 - >100)
Proliferation - SI (Mean, Range) 6.8 (0.8 - 36.6)
IL-5 - pg/mL (Mean, Range) 893 (0 - 11278)
IL-13 - pg/mL (Mean, Range) 849 (0 - 5433)
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Figure 1: Correlation between in vivo late phase skin response and in vitro T 
cell proliferation (A) and IL-13 secretion (B). 
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Figure 2: Correlation between nasal / asthmatic symptoms and in vivo early / 
late phase skin response. 
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